Literature DB >> 17487405

Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines.

Jun Murakami1, You-Jin Lee, Susumu Kokeguchi, Hidetsugu Tsujigiwa, Jun-Ichi Asaumi, Hitoshi Nagatsuka, Kazuhiro Fukui, Masahiro Kuroda, Noriaki Tanaka, Nagahide Matsubara.   

Abstract

O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme whose expression is controlled by its promoter methylation. A cell that expresses a low amount of MGMT is known to be more sensitive to the antiproliferative effects of alkylating agents. We have previously shown that the colorectal cancer patients treated with 5-fluorouracil (5-FU) as adjuvant chemotherapy had a better prognosis when the tumor revealed hypermethylation in its MGMT promoter. Therefore, we sought to investigate the relationship between the expression levels of MGMT and the anti-tumor effect of 5-FU in vitro by using two colon adenocarcinoma and four oral cancer cell lines with a variety of MGMT expression. We also investigated the effects of MGMT depletion by O6-benzylguanine (O6-BG), a potent inhibitor of MGMT. The 5-FU treatment uniformly depleted protein and mRNA expression of MGMT in all cell lines examined. Cell lines expressing low levels of MGMT were sensitive to 5-FU. On the other hand, cells expressing high levels of MGMT were less sensitive to 5-FU. The 5-FU treatment exhibited a better antiproliferative effect on the cells expressing high levels of MGMT by the pretreatment of O6-BG. Depletion of MGMT by O6-BG enhanced the anti-tumor effect of 5-FU. Assessment of the levels of MGMT expression in cancer cells and the control of its expression could contribute to the effective chemotherapy by 5-FU especially in patients who previously were considered as low-responsive individuals whose tumors have high levels of MGMT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17487405

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  23 in total

1.  Relationship Between the Expression of O6-Methylguanine-DNA Methyltransferase (MGMT) and p53, and the Clinical Response in Metastatic Pancreatic Adenocarcinoma Treated with FOLFIRINOX.

Authors:  Carole Vitellius; Caroline Eymerit-Morin; Dominique Luet; Lionel Fizanne; Fanny Foubert; Sandrine Bertrais; Marie-Christine Rousselet; François-Xavier Caroli-Bosc
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

Review 2.  Epigenetic mechanisms in oral carcinogenesis.

Authors:  Jacqueline A Gasche; Ajay Goel
Journal:  Future Oncol       Date:  2012-11       Impact factor: 3.404

3.  Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis.

Authors:  Francesca Spada; Patrick Maisonneuve; Caterina Fumagalli; Riccardo Marconcini; Fabio Gelsomino; Lorenzo Antonuzzo; Davide Campana; Ivana Puliafito; Giulio Rossi; Pinuccia Faviana; Luca Messerini; Massimo Barberis; Nicola Fazio
Journal:  Endocrine       Date:  2020-07-22       Impact factor: 3.633

4.  Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor.

Authors:  Louis de Mestier; Thomas Walter; Camille Evrard; Paul de Boissieu; Olivia Hentic; Jérôme Cros; David Tougeron; Catherine Lombard-Bohas; Vinciane Rebours; Pascal Hammel; Philippe Ruszniewski
Journal:  Neuroendocrinology       Date:  2019-05-10       Impact factor: 4.914

5.  Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.

Authors:  W Cai; N V Maldonado; W Cui; N Harutyunyan; L Ji; R Sposto; C P Reynolds; N Keshelava
Journal:  Br J Cancer       Date:  2010-10-05       Impact factor: 7.640

6.  Acetylation of Werner syndrome protein (WRN): relationships with DNA damage, DNA replication and DNA metabolic activities.

Authors:  Enerlyn Lozada; Jingjie Yi; Jianyuan Luo; David K Orren
Journal:  Biogerontology       Date:  2014-06-26       Impact factor: 4.277

7.  Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs.

Authors:  Renata D'Alpino Peixoto; Krista L Noonan; Peter Pavlovich; Hagen F Kennecke; Howard J Lim
Journal:  J Gastrointest Oncol       Date:  2014-08

Review 8.  New treatment options with cytotoxic agents in neuroendocrine tumours.

Authors:  Pascal Hammel; Olivia Hentic; Cindy Neuzillet; Sandrine Faivre; Eric Raymond; Philippe Ruszniewski
Journal:  Target Oncol       Date:  2012-08-22       Impact factor: 4.493

9.  Absence of MGMT promoter methylation in endometrial cancer.

Authors:  B J Rimel; Phyllis Huettner; Matthew A Powell; David G Mutch; Paul J Goodfellow
Journal:  Gynecol Oncol       Date:  2008-10-29       Impact factor: 5.482

10.  Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.

Authors:  Timothy F Cloughesy; Joseph Landolfi; Daniel J Hogan; Stephen Bloomfield; Bob Carter; Clark C Chen; J Bradley Elder; Steven N Kalkanis; Santosh Kesari; Albert Lai; Ian Y Lee; Linda M Liau; Tom Mikkelsen; Phioanh Leia Nghiemphu; David Piccioni; Tobias Walbert; Alice Chu; Asha Das; Oscar R Diago; Dawn Gammon; Harry E Gruber; Michelle Hanna; Douglas J Jolly; Noriyuki Kasahara; David McCarthy; Leah Mitchell; Derek Ostertag; Joan M Robbins; Maria Rodriguez-Aguirre; Michael A Vogelbaum
Journal:  Sci Transl Med       Date:  2016-06-01       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.